You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Nov 20, 2025

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Ninh M La-Beck1,2, Md Rakibul Islam1, Maciej M Markiewski1
1Department of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, TX, United States.
Nanoparticle anticancer drugs can cause immune reactions by activating complement. This immune response may reduce the effectiveness of nanoparticle drug delivery, highlighting the need for further research.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: